Bionime Corporation (TPE:4737)
Taiwan · Delayed Price · Currency is TWD 55.90
+1.10 (2.01%)
At close: Feb 11, 2026
Bionime Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 1,914 | 1,934 | 1,756 | 2,211 | 1,850 | 1,669 | |
Revenue Growth (YoY) | -0.38% | 10.15% | -20.58% | 19.50% | 10.87% | -23.21% |
Cost of Revenue | 1,272 | 1,165 | 1,040 | 1,206 | 1,067 | 919.46 |
Gross Profit | 641.61 | 768.38 | 715.65 | 1,004 | 783.13 | 749.13 |
Selling, General & Admin | 498.26 | 575.11 | 523.17 | 641.15 | 540.54 | 456.85 |
Research & Development | 273.77 | 322.33 | 242.34 | 201.98 | 187.86 | 247.88 |
Operating Expenses | 772.79 | 923.57 | 728.99 | 872.71 | 707.84 | 728 |
Operating Income | -131.18 | -155.19 | -13.34 | 131.42 | 75.29 | 21.12 |
Interest Expense | -63.96 | -62.19 | -48.23 | -30.65 | -19.05 | -21.55 |
Interest & Investment Income | 4.92 | 4.86 | 4.32 | 0.94 | 0.71 | 1.32 |
Currency Exchange Gain (Loss) | 12.65 | 7.41 | 5.24 | -14.96 | 0.94 | 4.39 |
Other Non Operating Income (Expenses) | 14.59 | 23.46 | 20.15 | 3.92 | 16.7 | 25.85 |
EBT Excluding Unusual Items | -162.99 | -181.66 | -31.86 | 90.67 | 74.6 | 31.12 |
Gain (Loss) on Sale of Investments | - | - | - | -0.01 | - | - |
Gain (Loss) on Sale of Assets | -3.14 | -0.08 | -0.01 | -4.17 | -0 | -0.02 |
Asset Writedown | -13.42 | -3.98 | - | - | - | - |
Other Unusual Items | - | - | - | - | -0.01 | 0.01 |
Pretax Income | -179.55 | -185.71 | -31.88 | 86.48 | 74.59 | 31.11 |
Income Tax Expense | -59.72 | -59.71 | -38.41 | -5.34 | -14.74 | -32.41 |
Earnings From Continuing Operations | -119.83 | -126 | 6.53 | 91.82 | 89.33 | 63.52 |
Minority Interest in Earnings | -0.52 | -1.22 | -0.32 | -0.8 | -1.91 | -1.09 |
Net Income | -120.35 | -127.22 | 6.21 | 91.03 | 87.41 | 62.43 |
Net Income to Common | -120.35 | -127.22 | 6.21 | 91.03 | 87.41 | 62.43 |
Net Income Growth | - | - | -93.18% | 4.13% | 40.01% | -41.24% |
Shares Outstanding (Basic) | 67 | 67 | 67 | 67 | 66 | 65 |
Shares Outstanding (Diluted) | 67 | 67 | 67 | 68 | 67 | 66 |
Shares Change (YoY) | 0.21% | -0.46% | -0.28% | 0.98% | 0.75% | 2.72% |
EPS (Basic) | -1.79 | -1.90 | 0.09 | 1.37 | 1.32 | 0.96 |
EPS (Diluted) | -1.80 | -1.90 | 0.09 | 1.35 | 1.31 | 0.94 |
EPS Growth | - | - | -93.25% | 2.78% | 39.80% | -43.09% |
Free Cash Flow | 132.72 | -166.55 | -89.64 | 4.62 | 132.25 | 88.28 |
Free Cash Flow Per Share | 1.98 | -2.48 | -1.33 | 0.07 | 1.98 | 1.33 |
Dividend Per Share | - | - | 1.818 | 1.909 | 1.818 | 1.875 |
Dividend Growth | - | - | -4.76% | 5.03% | -3.06% | 36.58% |
Gross Margin | 33.52% | 39.73% | 40.77% | 45.42% | 42.33% | 44.90% |
Operating Margin | -6.85% | -8.03% | -0.76% | 5.95% | 4.07% | 1.27% |
Profit Margin | -6.29% | -6.58% | 0.35% | 4.12% | 4.72% | 3.74% |
Free Cash Flow Margin | 6.93% | -8.61% | -5.11% | 0.21% | 7.15% | 5.29% |
EBITDA | 25.96 | 0.65 | 128.13 | 267.54 | 213.85 | 168.37 |
EBITDA Margin | 1.36% | 0.03% | 7.30% | 12.10% | 11.56% | 10.09% |
D&A For EBITDA | 157.14 | 155.84 | 141.47 | 136.12 | 138.55 | 147.25 |
EBIT | -131.18 | -155.19 | -13.34 | 131.42 | 75.29 | 21.12 |
EBIT Margin | -6.85% | -8.03% | -0.76% | 5.95% | 4.07% | 1.27% |
Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.